United Neuroscience to Present Data on Alzheimer's Vaccine at the 2019 AD/PD Conference
DUBLIN and DALLAS, March 28, 2019 /PRNewswire/ -- United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced an upcoming presentation on Phase IIa results of its lead clinical product, UB-311, at the 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Lisbon, Portugal, from March 26-31, 2019.
"UNS is working to solve some of the world's most difficult challenges, including those associated with Alzheimer's," said Mei Mei Hu, Chief Executive Officer of UNS. "As pioneers in developing endobody vaccines, we remain committed to transforming the lives of patients and families affected by neurodegenerative diseases."
Active Immunotherapy with UB-311 Vaccine: Results from a Phase IIA, Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter Study
Presenter: Jean-Cosme Dodart, Ph.D.
Date: Friday, March 29, 2019, 9:45 – 10:00 a.m. GMT
Location: Centro de Congressos de Lisboa, Plenary Hall – Auditorium I
Session Title: Symposium 32: Abeta Immunotherapies and BACE1 Inhibitors
About UB-311 in Alzheimer's Disease
Active vaccination of human individuals against Aβ has yet to be safely and effectively achieved. Other active vaccine efforts have either reported low antibody titers and responder rates or significant safety issues such as T-cell mediated encephalitis. UB-311 is a novel UBITh™ active vaccine targeting the N-terminus of Aβ peptides and is designed to induce high B-cell specific responses while avoiding T-cell inflammation. In the Phase I study, UB-311 vaccination safely elevated anti-Aβ antibodies in all patients with a suggestion of cognitive stabilization.
About United Neuroscience
United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of best-in-class active immunotherapeutics for the brain. A global company headquartered in Dublin, Ireland, with operations in Taiwan and the United States, UNS was founded to address the social and economic burden of Alzheimer's and other neurodegenerative diseases and seeks to rapidly advance candidates into and through clinical trials with the goal of delivering breakthrough treatments to patients. For more information please visit www.unitedneuroscience.com.
Follow UNS on Twitter at https://twitter.com/UNSTechBio and on LinkedIn at https://www.linkedin.com/company/unitedneuroscience.
SOURCE United Neuroscience